The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
Lawmakers are calling out advertisement of prescription of injectable weight-loss drugs without disclosing safety and risk information.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback